GLP-1 Obesity Drug Patents

GLP-1 obesity drug patents cover incretin-peptide composition-of-matter; dual and triple receptor-agonist innovations; oral-delivery and small-molecule innovations; and amylin, half-life-extension, and combination innovations — with IP held principally by the Novo Nordisk / Eli Lilly duopoly and a wave of challengers (in the largest pharmaceutical market of the decade). MAJOR GLP-1 PATENT HOLDERS: NOVO NORDISK: semaglutide — Ozempic (type 2 diabetes) and Wegovy (obesity), a once-weekly GLP-1 receptor agonist peptide — plus Rybelsus (ORAL semaglutide with the SNAC absorption enhancer), Saxenda (liraglutide), and pipeline CagriSema (cagrilintide, a long-acting amylin analog, + semaglutide) and oral amycretin; a deep incretin estate. ELI LILLY: tirzepatide — Mounjaro (diabetes) and Zepbound (obesity), a DUAL GIP/GLP-1 receptor agonist (hitting two incretin receptors for greater weight loss) — plus orforglipron (an ORAL non-peptide SMALL-MOLECULE GLP-1 agonist), retatrutide (a TRIPLE GIP/GLP-1/glucagon 'GGG' agonist), and the dual/triple-agonism estate. CHALLENGERS: Amgen (MariTide, a long-acting GIPR-antagonist/GLP-1 monthly), Pfizer (danuglipron oral small-molecule), Viking Therapeutics (VK2735), Structure Therapeutics, Zealand/Boehringer (survodutide GLP-1/glucagon), and (post-expiry) biosimilar/generic and compounding players. Incretin-peptide composition-of-matter, multi-receptor agonism, oral delivery, and amylin are the core GLP-1 patent domains.

Peptide-composition-of-matter innovations; receptor-agonism and selectivity innovations; multi-receptor (dual/triple) innovations; and half-life-extension innovations represent core GLP-1 patent domains — and the specific peptide molecule (a new chemical entity) is the durable composition-of-matter asset. PEPTIDE COMPOSITION-OF-MATTER PATENTS: the specific incretin-mimetic peptide sequence and modifications — semaglutide and tirzepatide are distinct, patented peptides claimed as composition-of-matter (the ~20-year core protection any drug gets) — including the amino-acid sequence, unnatural amino acids (e.g. AIB at position 2 for DPP-4 resistance), and the overall molecule. RECEPTOR-AGONISM PATENTS: GLP-1 receptor agonism (the core appetite/glucose mechanism), and the rational design for potency/selectivity. MULTI-RECEPTOR PATENTS: DUAL agonism (GIP + GLP-1 — tirzepatide, a single peptide engineered to activate both incretin receptors, giving greater weight loss) and TRIPLE agonism (adding glucagon-receptor agonism for energy expenditure — retatrutide 'GGG'); the multi-receptor-balanced peptide and the agonism ratios are key, high-value claims (this is the current efficacy frontier). HALF-LIFE-EXTENSION PATENTS: fatty-acid acylation (a lipid chain that binds serum albumin to extend half-life to once-weekly — central to semaglutide/tirzepatide dosing), and other long-acting modifications. The specific peptide (composition-of-matter), the multi-receptor agonism balance, and the half-life-extension modification are the highest-value GLP-1 IP — and because these are concrete molecules, they are §101-strong (unlike software).

Oral-peptide-delivery innovations; oral small-molecule (non-peptide) innovations; amylin and other-mechanism innovations; and formulation, manufacturing, and combination innovations represent additional GLP-1 patent domains — and the move to oral and to non-peptide small molecules is the next competitive battleground. ORAL-PEPTIDE PATENTS: enabling a peptide (normally destroyed in the gut) to be taken orally — the SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) absorption enhancer that lets oral semaglutide (Rybelsus) cross the stomach lining, formulation, and dosing; oral-peptide delivery is a distinct, valuable platform. ORAL SMALL-MOLECULE PATENTS: NON-PEPTIDE small molecules that agonize the GLP-1 receptor (orforglipron, danuglipron, VK2735-oral) — these can be made cheaply at scale and taken as a daily pill (a huge cost/access advantage over injectable peptides), so the small-molecule chemotype (composition-of-matter) is the highest-value next-generation race. AMYLIN / OTHER-MECHANISM PATENTS: long-acting amylin analogs (cagrilintide — complementary satiety mechanism, combined with semaglutide in CagriSema), and other targets (GIPR antagonism — Amgen MariTide, glucagon). FORMULATION / MANUFACTURING / COMBINATION PATENTS: peptide manufacturing (solid-phase/recombinant synthesis at massive scale — a real supply constraint), auto-injector/device, formulation/stability, dosing titration, and fixed-dose combinations; these extend exclusivity beyond the core composition (the 'patent thicket' that lengthens a franchise). Oral small-molecule GLP-1 agonists and amylin/multi-mechanism combinations are the highest-value forward-looking GLP-1 IP.

GLP-1 startup IP strategy must navigate Novo Nordisk semaglutide and Eli Lilly tirzepatide composition-of-matter and patent-thicket estates, the looming COMPOSITION-OF-MATTER EXPIRIES (semaglutide's core patents begin expiring around 2026 in some markets — e.g. it has lapsed/expires earlier in India, Brazil, and elsewhere — opening biosimilars/generics, while US/EU core protection and formulation patents extend further; tirzepatide is newer with later expiry), the manufacturing/supply constraints, compounding-pharmacy dynamics during shortages, and a §101-strong (composition-of-matter) but fiercely-competitive landscape; understand that the core peptides are composition-of-matter (durable but expiring), that the open, high-value frontiers are oral SMALL-MOLECULE agonists, novel multi-receptor balances, amylin/combination mechanisms, and improved manufacturing, and that timing (around expiries) and manufacturing scale matter enormously; identify whitespace in oral small molecules, novel agonism profiles, amylin/combinations, and biosimilars/manufacturing. GLP-1 STARTUP IP STRATEGY: THE CORE PEPTIDES ARE COMPOSITION-OF-MATTER (DURABLE BUT EXPIRING) — TIMING IS EVERYTHING: semaglutide's core patents are beginning to expire in various markets (sooner outside the US — India/Brazil already, US/EU core later with formulation extensions); tirzepatide expires later — strategy depends heavily on the geography and date, so map the exact composition + formulation expiry per market; ORAL SMALL-MOLECULE AGONISTS ARE THE HIGHEST-VALUE WHITESPACE: a non-peptide oral GLP-1 agonist (orforglipron-class) can be made cheaply and taken as a daily pill — the biggest cost/access prize and the most active next-generation patent race; a novel small-molecule chemotype is durable composition-of-matter; NOVEL MULTI-RECEPTOR BALANCES AND AMYLIN/COMBINATIONS ARE OPEN: distinct dual/triple agonism ratios, amylin analogs, GIPR-antagonism, and muscle-sparing combinations are differentiated, patentable efficacy/tolerability angles; MANUFACTURING SCALE IS A REAL MOAT: peptide synthesis at massive scale is supply-constrained — manufacturing IP and capacity matter; BIOSIMILAR/GENERIC AND FORMULATION PLAYS FOLLOW EXPIRY: post-expiry biosimilar semaglutide and improved formulations/devices are commercial opportunities (navigate the formulation patent thicket); §101 IS NOT THE ISSUE — THESE ARE MOLECULES: composition-of-matter is strong; the battle is competition, expiry timing, and manufacturing, not patentability; WHEN TO PATENT: NOVEL MOLECULE/FORMULATION WITH MEASURED EFFICACY: file composition-of-matter once a peptide/small-molecule shows measured results (receptor agonism/selectivity + weight loss % + tolerability + oral bioavailability + dosing/half-life) — measured weight loss, tolerability, oral bioavailability, and receptor profile are the critical GLP-1 IP metrics; KEY FTO CHECKLIST: Novo semaglutide composition-of-matter + AIB-2/fatty-acid-acylation + SNAC oral (Rybelsus) + CagriSema amylin; Lilly tirzepatide dual GIP/GLP-1 + orforglipron oral small-molecule + retatrutide triple GGG; Amgen MariTide GIPR-antagonist/GLP-1; Pfizer danuglipron/Viking VK2735/Structure oral small-molecule; fatty-acid acylation albumin-binding half-life; oral-peptide SNAC absorption enhancer; amylin/glucagon/GIPR multi-mechanism; peptide manufacturing scale; composition + formulation patent expiry by market (semaglutide ~2026+ varies, tirzepatide later); biosimilar/compounding.